Beta-Thalassaemia — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Not so benign: Life-threatening hematuria from renal papillary necrosis in sickle cell trait.
Hodgen Katharine et al. — Urology case reports (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42291484/
- 2.
Assessment of hepatic fibrosis in Egyptian children and adolescents with beta thalassemia major: a single center study.
Elhady Marwa Abd et al. — European journal of pediatrics (27 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42362985/
- 3.
Diagnostic potential of Q-flags (RBC agglutination? and fragments?) in beta thalassemia carriers: a comparative analysis with nutritional anemias.
Shaikh Muhammad Shariq et al. — Journal of hematopathology (25 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42350848/
- 4.
Evaluation of heart rate variability in pediatric patients with beta thalassemia major: Cross-sectional study.
Sorour Esraa A et al. — World journal of clinical pediatrics (9 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42220932/
- 5.
Investigating beta-thalassaemia in micro-CT scans of deciduous teeth.
Garnett Elizabeth M et al. — International journal of paleopathology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41775229/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Beta-Thalassaemia
Beta-thalassaemia is an inherited blood disorder caused by mutations in the HBB gene that reduce or eliminate production of the beta-globin protein, leading to anaemia of varying severity. The severe form (thalassaemia major) requires lifelong blood transfusions. Gene therapies and gene editing approaches are transforming treatment options.
Most Recent Research
Renal papillary necrosis (RPN) is an uncommon but important cause of hematuria in patients with sickle cell trait. We report a 28-year-old female with sickle cell trait and beta thalassemia who developed recurrent, transfusion-dependent gross hematuria. Despite extensive imaging, endoscopic evaluation, and conservative management, bleeding persisted. Ureteroscopy demonstrated findings consistent with RPN. The patient required intensive multidisciplinary care and 21 units of packed red blood cells. Hematuria ultimately resolved following treatment with oral epsilon-aminocaproic acid. This case highlights the potential severity of RPN in sickle cell trait and supports consideration of antifibrinolytics as salvage therapy in refractory cases.
Common Questions
What is Beta-Thalassaemia?
Beta-thalassaemia is an inherited blood disorder caused by mutations in the HBB gene that reduce or eliminate production of the beta-globin protein, leading to anaemia of varying severity. The severe form (thalassaemia major) requires lifelong blood transfusions. Gene therapies and gene editing approaches are transforming treatment options.
How many clinical trials are available for Beta-Thalassaemia?
RareWays currently indexes 69 clinical trials for Beta-Thalassaemia, of which 12 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Beta-Thalassaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Beta-Thalassaemia.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.